Lumito is contributing with a poster presentation describing the Company’s technology and its potential within digital pathology. Participation enables relevant meetings with stakeholders in AI, CRO, and Pharma, and provides Lumito with opportunities to broaden its dialogue with organisations working with integrated digital imaging and precision medicine.

”The Digital Pathology & AI Congress is a well-chosen forum for presenting our technology and deepening the dialogue with stakeholders working close to the processes where our product can make a difference. Being present in London is also a concrete part of our intensified commercialisation efforts, which we can now pursue with increased momentum”, says Sanna Wallenborg, CEO of Lumito.

As the proceeds from the share issue and the recently approved grant from Region Skåne have strengthened the Company’s financial position, activities are being carried out in the areas of marketing, visibility, and partner dialogues. Participation in national and international conferences is one of the areas the Company is accelerating to support continued market introduction and commercialisation initiatives.